AstraZeneca Pauses $833.2 Million UK Investment

AstraZeneca's planned investment of 650 million pounds in the UK for vaccine research and development is currently on hold. The company is in ongoing negotiations with the UK government to discuss possible incentives. No new developments have been reported after the company's recent third-quarter earnings announcement.

London-listed pharmaceutical giant AstraZeneca has put its 650 million pound vaccine research and development investment in the UK on hold. The investment plan, first revealed in March, remains in limbo as discussions with the UK government proceed.

AstraZeneca's Chief Financial Officer, Aradhana Sarin, stated during a media briefing that the company is still negotiating potential incentives with the government. "We don't have anything new to report at this time," Sarin confirmed, following the publication of the company's third-quarter financial results.

The currency exchange rate is currently pegged at $1 for 0.7802 pounds.

(With inputs from agencies.)